Table 2. Summary data on all comparisons with survival as the end point.
| Group | Rate difference (95% c.i.) | P het. | P sig. | RR (95% c.i.) | P het. | P sig. | Events | Total |
|---|---|---|---|---|---|---|---|---|
| IHC | ||||||||
| All | 0.13 (0.10–0.16) | <0.0001 | <0.0001 | 1.32 (1.23–1.42) | <0.0001 | <0.0001 | 5087 | 12 257 |
| DO-7 | 0.10 (0.05–1.14) | <0.0001 | <0.0001 | 1.24 (1.12–1.37) | <0.0001 | <0.0001 | 2566 | 6436 |
| Pab-1801 | 0.16 (0.09–0.23) | 0.05 | <0.0001 | 1.40 (1.18–1.66) | 0.132 | <0.0001 | 511 | 1281 |
| Others | 0.15 (0.10–0.21) | <0.0001 | <0.0001 | 1.43 (1.25–1.63) | <0.0001 | <0.0001 | 2010 | 4540 |
| Mutations | 0.12 (0.08–0.17) | <0.0001 | <0.0001 | 1.31 (1.19–1.45) | <0.0001 | <0.0001 | 3128 | 6645 |
IHC=immunohistochemical detection of accumulation of p53; DO-7=studies using the DO-7 antibody; Pab-1801=studies using the antibody Pab-1801; others=all other IHC studies; mutations=studies in which p53 mutations were identified using sequencing; RR=relative risk; c.i.=confidence interval; P het.=the P value, derived from the Q statistic, for heterogeneity/homogeneity. The lower the P-value, the less likely it is that the studies in the analysis are homogeneous: low P-values indicate heterogeneity. P sig.=the P-value for the observed effect; events=deaths; total=total number of patients in each analysis.